(S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorothioyl)amino)propanoate | 1365634-50-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorothioyl)amino)propanoate
• 英文别名: (2S)-isopropyl 2-(((((2R,3R.4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorothioyl)amino)propanoate；2'-C-methyluridine 5'-phenyl-N-(S)-1-((isopropoxycarbonyl)ethyl)thiophosphoramidate；2'-methyluridine；propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphinothioyl]amino]propanoate
• CAS: 1365634-50-9
• 化学式: C₂₂H₃₀N₃O₉PS
• 分子量: 543.535
• InChiKey: XFJMOMBVBMXWCV-UWJKSZNLSA-N

物化性质

• 密度：
  1.409±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  188
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  (S)-isopropyl 2-(((S)-(((3aR,4R,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2,6a-trimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphorothioyl)amino)propanoate 在 三氟乙酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 6.0h， 以15.5 g的产率得到(S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorothioyl)amino)propanoate
  参考文献：
  名称：

  [EN] METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS
  [FR] MÉTHODES DE SYNTHÈSE STÉRÉOSÉLECTIVE D'ANALOGUES NUCLÉOSIDIQUES SUBSTITUÉS

  摘要：

  公开号：

  WO2014164533A8

文献信息

• DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20140309164A1

  公开（公告）日：2014-10-16

  Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure The variables, e.g., B 1 , Y, R 1 , R 2 , R 3 , R 3 ′, R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 carry definitions set forth in the disclosure. Compounds of Formula (I) are deuterated at one or more positions and the deuterium enrichment at each deuterated positions is at least 50%. Compounds and salts of Formula (I) are useful for treating viral infections, including HCV infections.

  本公开提供了式（I）的氘代核苷类似物及其药用盐。变量，例如B1、Y、R1、R2、R3、R3'、R4、R5、R6、R7、R8和R9在本公开中有定义。式（I）的化合物在一个或多个位置上被氘代，且每个氘代位置的氘富集度至少为50%。式（I）的化合物和盐对治疗病毒感染，包括HCV感染，具有用处。
• SUBSTITUTED NUCLEOTIDE ANALOGS
  申请人：Smith David Bernard

  公开号：US20120071434A1

  公开（公告）日：2012-03-22

  Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.

  本文披露了磷酸硫代酯核苷类似物，合成磷酸硫代酯核苷类似物的方法，以及利用磷酸硫代酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。
• METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS
  申请人：ALIOS BIOPHARMA, INC.

  公开号：US20130253181A1

  公开（公告）日：2013-09-26

  Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.

  本文披露了一种制备磷酸硫酯核苷酸类似物的方法，该方法对于治疗病毒感染等疾病和/或病况非常有用。
• METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140309413A1

  公开（公告）日：2014-10-16

  The present invention relates to the novel diastereoselective syntheses for generating phosphorothioate compounds. Examples include nucleoside phosphorothioate analogs that are useful in treating diseases and/or conditions such as viral infections.

  本发明涉及一种新型对映选择性合成方法，用于生成磷酸硫酯化合物。其中包括核苷酸磷酸硫酯类似物，可用于治疗病毒感染等疾病和/或病况。
• [EN] SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PRODRUG<br/>[FR] FORMES SOLIDES D'UN PROMÉDICAMENT NUCLÉOTIDIQUE THIOPHOSPHORAMIDATE
  申请人：VERTEX PHARMA

  公开号：WO2013142124A8

  公开（公告）日：2014-05-15